Applied Therapeutics Announces Start of AT-007 Pediatric Galactosemia Study; Releases Additional 40mg/kg Data from Adult Galactosemia Study

NEXT STORY
Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider
PREV STORY
Global Immunotherapy Drugs Market (2020 to 2025) – Increased Demand for Personalized Medicines Presents Opportunities
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing

CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company ...

author_avatar
NASDAQ Market News

Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference

OXFORD, United Kingdom and CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics ...

author_avatar
NASDAQ Market News

UPDATE — ZEMDRI™ (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)

― ZEMDRI is a new treatment for patients with cUTI, including pyelonephritis, due to ...

author_avatar
NASDAQ Market News